Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPensionPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Gain Therapeutics (GANX) Retained Earnings (2020 - 2025)

Gain Therapeutics has reported Retained Earnings over the past 6 years, most recently at $563221.0 for Q3 2025.

  • Quarterly results put Retained Earnings at $563221.0 for Q3 2025, up 131.96% from a year ago — trailing twelve months through Sep 2025 was $563221.0 (up 131.96% YoY), and the annual figure for FY2024 was -$60.8 million, down 24684.8%.
  • Retained Earnings for Q3 2025 was $563221.0 at Gain Therapeutics, down from $584083.0 in the prior quarter.
  • Over the last five years, Retained Earnings for GANX hit a ceiling of $584083.0 in Q2 2025 and a floor of -$81.2 million in Q1 2025.
  • Median Retained Earnings over the past 5 years was -$296900.0 (2022), compared with a mean of -$15.9 million.
  • Biggest five-year swings in Retained Earnings: skyrocketed 593.97% in 2023 and later tumbled 371480.45% in 2025.
  • Gain Therapeutics' Retained Earnings stood at -$7.0 million in 2021, then skyrocketed by 100.51% to $35627.0 in 2022, then skyrocketed by 593.97% to $247241.0 in 2023, then plummeted by 24684.8% to -$60.8 million in 2024, then soared by 100.93% to $563221.0 in 2025.
  • The last three reported values for Retained Earnings were $563221.0 (Q3 2025), $584083.0 (Q2 2025), and -$81.2 million (Q1 2025) per Business Quant data.